» Articles » PMID: 9443166

The Role of Non-P450 Enzymes in Drug Oxidation

Overview
Journal Pharm World Sci
Publisher Springer
Specialties Pharmacology
Pharmacy
Date 1998 Jan 27
PMID 9443166
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

In addition to cytochrome P450, oxidation of drugs and other xenobiotics can also be mediated by non-P450 enzymes, the most significant of which are flavin monooxygenase, monoamine oxidase, alcohol dehydrogenase, aldehyde dehydrogenase, aldehyde oxidase and xanthine oxidase. This article highlights the importance of these non-P450 enzymes in drug metabolism. A brief introduction to each of the non-P450 oxidizing enzymes is given in this review and the oxidative reactions have been illustrated with clinical examples. Drug oxidation catalyzed by enzymes such as flavin monooxygenase and monoamine oxidase may often produce the same metablolites as those generated by P450 adn thus drug interactions may be difficult to predict without a clear knowledge of the underlying enzymology. In contrast, oxidation via aldehyde oxidase and xanthine oxidase gives different metabolites to those resulting from P450 hydroxylation. Although oxidation catalyzed by non-P450 enzymes can lead to drug inactivation, oxidation may be essential for the generation of active metabolite(s). The activation of a number of prodrugs by non-P450 enzymes is thus described. It is concluded that there is still much to learn about factors affecting the non-P450 enzymes in the clinical situation.

Citing Articles

Single-Nucleotide Polymorphisms as Biomarkers of Antipsychotic-Induced Akathisia: Systematic Review.

Nasyrova R, Vaiman E, Repkina V, Khasanova A, Asadullin A, Shipulin G Genes (Basel). 2023; 14(3).

PMID: 36980888 PMC: 10048266. DOI: 10.3390/genes14030616.


How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?.

Henriques B, Yang E, Lapetina D, Carr M, Yavorskyy V, Hague J Front Genet. 2020; 11:491895.

PMID: 33363564 PMC: 7753050. DOI: 10.3389/fgene.2020.491895.


Systematic exploration of predicted destabilizing nonsynonymous single nucleotide polymorphisms (nsSNPs) of human aldehyde oxidase: A Bio-informatics study.

Coelho C, Muthukumaran J, Santos-Silva T, Romao M Pharmacol Res Perspect. 2019; 7(6):e00538.

PMID: 31768259 PMC: 6874515. DOI: 10.1002/prp2.538.


A single nucleotide polymorphism causes enhanced radical oxygen species production by human aldehyde oxidase.

Foti A, Dorendorf F, Leimkuhler S PLoS One. 2017; 12(7):e0182061.

PMID: 28750088 PMC: 5531472. DOI: 10.1371/journal.pone.0182061.


Xanthine Oxidoreductase in Drug Metabolism: Beyond a Role as a Detoxifying Enzyme.

Battelli M, Polito L, Bortolotti M, Bolognesi A Curr Med Chem. 2016; 23(35):4027-4036.

PMID: 27458036 PMC: 5345321. DOI: 10.2174/0929867323666160725091915.


References
1.
Cashman J . Enantioselective N-oxygenation of verapamil by the hepatic flavin-containing monooxygenase. Mol Pharmacol. 1989; 36(3):497-503. View

2.
Brunner H, Nelen M, Breakefield X, Ropers H, van Oost B . Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science. 1993; 262(5133):578-80. DOI: 10.1126/science.8211186. View

3.
Novoradovsky A, Tsai S, Goldfarb L, Peterson R, Long J, Goldman D . Mitochondrial aldehyde dehydrogenase polymorphism in Asian and American Indian populations: detection of new ALDH2 alleles. Alcohol Clin Exp Res. 1995; 19(5):1105-10. DOI: 10.1111/j.1530-0277.1995.tb01587.x. View

4.
Cambridge D . UK-14,304, a potent and selective alpha2-agonist for the characterisation of alpha-adrenoceptor subtypes. Eur J Pharmacol. 1981; 72(4):413-5. DOI: 10.1016/0014-2999(81)90588-4. View

5.
DIXON C, Park G, Tarbit M . Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem Pharmacol. 1994; 47(7):1253-7. DOI: 10.1016/0006-2952(94)90397-2. View